

Emilio Alba

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4006547/emilio-alba-publications-by-year.pdf>

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

204 papers	6,481 citations	45 h-index	76 g-index
238 ext. papers	7,759 ext. citations	4.8 avg, IF	5.12 L-index

#	Paper	IF	Citations
204	Abstract P4-07-10: Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain. <i>Cancer Research</i> , 2022 , 82, P4-07-10-P4-07-10	10.1	
203	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.. <i>Frontiers in Oncology</i> , 2021 , 11, 827625	5.3	1
202	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.. <i>New England Journal of Medicine</i> , 2021 , 385, 2336-2347	59.2	45
201	Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	4
200	Structural validity and reliability of the Spanish Central Sensitization Inventory in breast cancer survivors. <i>Pain Practice</i> , 2021 , 21, 740-746	3	1
199	Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study. <i>Cancers</i> , 2021 , 13,	6.6	6
198	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 462-470	6.1	0
197	Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021 , 144, 224-231	7.5	4
196	CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients. <i>Nutrients</i> , 2021 , 13,	6.7	4
195	Design and implementation of a standard care programme of therapeutic exercise and education for breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
194	The role of CDK4/6 inhibitors in early breast cancer. <i>Breast</i> , 2021 , 58, 160-169	3.6	5
193	Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2021 , 1	2.3	1
192	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021 , 66, 951-959	6.1	4
191	Energy System Assessment in Survivors of Breast Cancer. <i>Physical Therapy</i> , 2020 , 100, 438-446	3.3	5
190	Inertial Sensors Embedded in Smartphones as a Tool for Fatigue Assessment Based on Acceleration in Survivors of Breast Cancer. <i>Physical Therapy</i> , 2020 , 100, 447-456	3.3	6
189	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	33
188	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. <i>EBioMedicine</i> , 2020 , 62, 103100	8.8	14

187	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. <i>Cancers</i> , 2020 , 12,	6.6	1
186	Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. <i>Cancers</i> , 2020 , 12,	6.6	26
185	GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients. <i>Nutrients</i> , 2019 , 11,	6.7	64
184	Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index. <i>PLoS ONE</i> , 2019 , 14, e0215662	3.7	5
183	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
182	Detection of and Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	21
181	Targeted treatment approaches in refractory germ cell tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 130-138	7	11
180	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , 2019 , 10, 4321-4332	3.3	
179	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019 , 9, 1124	5.3	32
178	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019 , 9, 1178	5.3	4
177	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry). <i>Scientific Reports</i> , 2019 , 9, 20081	4.9	6
176	Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2019 , 21, 534-538	3.6	
175	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. <i>Psycho-Oncology</i> , 2018 , 27, 1530-1537	3.9	19
174	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. <i>Breast Cancer Research and Treatment</i> , 2018 , 170, 535-545	4.4	49
173	Central sensitization in breast cancer survivors. <i>Journal of Applied Biobehavioral Research</i> , 2018 , 23, e12129	12.9	3
172	First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 469-479	4.4	29
171	Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers. <i>Experimental and Molecular Pathology</i> , 2018 , 104, 161-169	4.4	14
170	Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , 2018 , 94, 199-205	7.5	14

169	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 659-669	4.4	45
168	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. <i>Modern Pathology</i> , 2018 , 31, 299-306	9.8	9
167	Grado de acuerdo entre la acelerometría y el Cuestionario Internacional de Actividad Física en pacientes supervivientes de cáncer de mama. <i>Fisioterapia</i> , 2018 , 40, 26-35	0.2	
166	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. <i>Pathology and Oncology Research</i> , 2018 , 24, 871-879	2.6	4
165	Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial. <i>BMC Complementary and Alternative Medicine</i> , 2018 , 18, 180	4.7	6
164	Hereditary breast and ovarian cancer in Andalusian families: a genetic population study. <i>BMC Cancer</i> , 2018 , 18, 647	4.8	4
163	Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 579-579	2.2	3
162	Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12073-12073	2.2	
161	Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 592-592	2.2	
160	Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients. <i>Clinical and Translational Oncology</i> , 2018 , 20, 922-927	3.6	17
159	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018 , 9, 26406-26416	3.3	76
158	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018 , 20, 1548-1556	3.6	9
157	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017 , 23, 3035-3044	12.9	17
156	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 1432-1441	12.9	25
155	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , 2017 , 28, 2943-2949	10.3	51
154	Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers 2017 ,		9
153	Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2-advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial 2017 ,		3
152	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1020-1020	2.2	12

151	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1047-1047	2.2	4
150	Health-related quality of life of postmenopausal women with hormone receptor-positive, HER2-advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 133-133	2.2	2
149	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017 , 8, 21473-21482	3.3	2
148	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016 , 22, 560-6	12.9	57
147	Supervised discretization can discover risk groups in cancer survival analysis. <i>Computer Methods and Programs in Biomedicine</i> , 2016 , 136, 11-9	6.9	3
146	Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 8	2.8	0
145	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1585-1585	2.2	1
144	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016 , 7, 37680-37692	3.3	30
143	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016 , 16, 415-28	2.8	8
142	Outcomes of single versus double hormone receptor positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 569-569	2.2	
141	Advanced Online Survival Analysis Tool for Predictive Modelling in Clinical Data Science. <i>PLoS ONE</i> , 2016 , 11, e0161135	3.7	1
140	Winding number order in the Haldane model with interactions. <i>New Journal of Physics</i> , 2016 , 18, 033022	2.9	3
139	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. <i>BMC Cancer</i> , 2016 , 16, 829	4.8	0
138	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Oncologist</i> , 2016 , 21, 150-5	5.7	21
137	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975
136	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1286-94	1.9	9
135	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015 , 26, 1280-91	10.3	127
134	Defining breast cancer intrinsic subtypes by quantitative receptor expression. <i>Oncologist</i> , 2015 , 20, 474-87	3.7	102

133	Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 343-7	3	9
132	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 569-569	2.2	
131	The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. <i>Cancer Treatment Reviews</i> , 2014 , 40, 293-9	14.4	37
130	Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. <i>British Journal of Cancer</i> , 2014 , 110, 1139-47	8.7	48
129	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1532-41	8.7	82
128	Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. <i>Clinical and Translational Oncology</i> , 2014 , 16, 548-54	3.6	10
127	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1351-60	21.7	102
126	A microRNA signature associated with early recurrence in breast cancer. <i>PLoS ONE</i> , 2014 , 9, e91884	3.7	64
125	Time to diagnosis of ewing tumors in children and adolescents is not associated with metastasis or survival. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4020	2.2	4
124	Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 231-7	1.9	9
123	Adjuvant high-dose interferon therapy for melanoma: nothing has really changed. <i>Melanoma Research</i> , 2014 , 24, 522-3	3.3	
122	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , 2014 , 16, R38	8.3	97
121	Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. <i>Clinical and Translational Oncology</i> , 2014 , 16, 418-24	3.6	7
120	Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1024-7	10.2	1024
119	Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. <i>BMC Cancer</i> , 2013 , 13, 26	4.8	25
118	Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 85, 315-31	7	20
117	The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. <i>Clinical Breast Cancer</i> , 2013 , 13, 146-52	3	17
116	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 381-91	2.2	14

115	18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. <i>European Journal of Cancer</i> , 2013 , 49, 3573-4	7.5	
114	Addressing critical issues in the development of an Oncology Information System. <i>International Journal of Medical Informatics</i> , 2013 , 82, 398-407	5.3	16
113	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. <i>Oral Oncology</i> , 2013 , 49, 182-5	4.4	31
112	SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). <i>Clinical and Translational Oncology</i> , 2013 , 15, 20-5	3.6	5
111	Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. <i>Anti-Cancer Drugs</i> , 2013 , 24, 975-9	2.4	
110	Proliferation determined by ki67 marker and pCR in locally advanced breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Journal</i> , 2013 , 19, 685-6	1.2	4
109	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. <i>Breast Cancer Research</i> , 2013 , 15, R98	8.3	69
108	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013 , 15, R105	8.3	50
107	New insights into the role of the immune microenvironment in breast carcinoma. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 785317		45
106	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 487-93	4.4	106
105	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. <i>BMC Medical Genomics</i> , 2012 , 5, 44	3.7	199
104	Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 444-51	7	4
103	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012 , 14, 820-6	3.6	1
102	Practical guidelines for dose individualization of anticancer targeted drugs. <i>Clinical and Translational Oncology</i> , 2012 , 14, 812-9	3.6	
101	Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. <i>Annals of Oncology</i> , 2012 , 23, 3069-3074	10.3	123
100	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. <i>Clinical and Translational Oncology</i> , 2012 , 14, 94-101	3.6	24
99	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012 , 14, 423-9	3.6	6
98	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 625-631	10.3	93

97	Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. <i>Oncology</i> , 2012 , 83, 228-33	3.6	11
96	Serum protein levels following surgery in breast cancer patients: a protein microarray approach. <i>International Journal of Oncology</i> , 2012 , 41, 2200-6	4.4	21
95	Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial. 2012 ,		2
94	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , 2011 , 12, 369-76	21.7	68
93	Outcome of small invasive breast cancer with no axillary lymph node involvement. <i>Breast Journal</i> , 2011 , 17, 32-8	1.2	6
92	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. <i>Breast</i> , 2011 , 20, S43	3.6	3
91	Regional and seasonal influence in patient toxicity to adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 273-8	4.4	4
90	Multimodal treatment of desmoid tumours: the significance of local control. <i>Clinical and Translational Oncology</i> , 2011 , 13, 189-93	3.6	6
89	Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. <i>Clinical and Translational Oncology</i> , 2011 , 13, 426-9	3.6	17
88	Update on the diagnosis of cancer of unknown primary (CUP) origin. <i>Clinical and Translational Oncology</i> , 2011 , 13, 434-41	3.6	6
87	Antiangiogenic therapy of breast cancer: how did we get here?: the road not taken. <i>Clinical and Translational Oncology</i> , 2011 , 13, 765-6	3.6	1
86	Cross-sensitivity between taxanes in patients with breast cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 904-6	3.6	11
85	Seeing topological order in time-of-flight measurements. <i>Physical Review Letters</i> , 2011 , 107, 235301	7.4	149
84	Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03A multicenter, randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1015-1015	2.2	3
83	Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5528-5528	2.2	3
82	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 5594-5594	2.2	3
81	Mapping the spatial distribution of entanglement in optical lattices. <i>Physical Review A</i> , 2010 , 82,	2.6	9
80	Adjuvant docetaxel for high-risk, node-negative breast cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 2200-10	59.2	149

79	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. <i>Oncology</i> , 2010 , 79, 98-104	3.6	43
78	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010 , 12, 278-86	3.6	2
77	Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. <i>Clinical and Translational Oncology</i> , 2010 , 12, 614-20	3.6	6
76	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 149-57	4.4	63
75	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 591-600	4.4	33
74	Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 169-76	4.4	61
73	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. <i>BMC Cancer</i> , 2010 , 10, 136	4.8	44
72	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. <i>Artificial Intelligence in Medicine</i> , 2010 , 50, 105-15	7.4	240
71	Prognosis of microinvasive breast carcinoma with negative axillary nodes in accordance with TNM classification criteria. <i>Breast Journal</i> , 2010 , 16, 669-71	1.2	5
70	Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 500-500	2.2	11
69	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2010 , 28, e15507-e15507	2.2	2
68	Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. <i>Oncology</i> , 2009 , 76, 133-41	3.6	30
67	Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice. <i>Journal of Clinical Oncology</i> , 2009 , 27, e255-6; author reply e257-8	2.2	
66	Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. <i>Oncologist</i> , 2009 , 14, 1-11	5.7	100
65	Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2009 , 11, 329-31	3.6	5
64	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009 , 11, 363-75	3.6	11
63	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009 , 11, 727-36	3.6	2
62	Recomendaci3n para la determinaci3n de HER2 en c3ncer de mama. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica (SEAP) y de la Sociedad Espa3ola de Oncolog3a M3dica (SEOM). <i>Revista Espanola De Patologia</i> , 2009 , 42, 3-16	1.2	3

61	Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. <i>BMC Cancer</i> , 2008 , 8, 174	4.8	27
60	Time-to-progression in breast cancer: a stratification model for clinical trials. <i>Breast</i> , 2008 , 17, 239-44	3.6	1
59	Maintenance treatment in metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1907-12	3.5	33
58	The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. <i>Journal of Biological Chemistry</i> , 2008 , 283, 17450-62	5.4	28
57	A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. <i>Current Drug Metabolism</i> , 2008 , 9, 336-43	3.5	56
56	A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 811-6	12.9	104
55	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 805-14	9.7	174
54	Out of blue hermitte sign: three cases due to low cumulative doses of oxaliplatin. <i>Annals of Oncology</i> , 2008 , 19, 2093-4	10.3	5
53	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. <i>Clinical and Translational Oncology</i> , 2008 , 10, 552-9	3.6	1
52	Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2008 , 10, 583-6	3.6	56
51	Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 400-5		13
50	Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. <i>BioEssays</i> , 2007 , 29, 1159-68	4.1	69
49	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. <i>Cancer</i> , 2007 , 110, 2178-85	6.4	10
48	Prognostic value of serum angiogenic activity in colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2007 , 11, 120-8	5.6	10
47	Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). <i>Breast Cancer Research and Treatment</i> , 2007 , 101, 215-23	4.4	45
46	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 375-84	3.6	3
45	Erythropoietin pharmacology. <i>Clinical and Translational Oncology</i> , 2007 , 9, 715-22	3.6	16
44	Presentation of Hodgkin lymphoma with Ophelia syndrome. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1802-3		9

43	Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. <i>Cancer Biomarkers</i> , 2007 , 3, 325-33	3.8	14
42	Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 200101 study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1007-1007	2.2	15
41	Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECp): Relevance of HER2 and hormonal status (HR). <i>Journal of Clinical Oncology</i> , 2007 , 25, 10598-10598	2.2	5
40	Prognostic value of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (pts) included in phase III trials of adjuvant therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 21040-21040	2.2	
39	Early Breast Cancer Prognosis Prediction and Rule Extraction Using a New Constructive Neural Network Algorithm 2007 , 1004-1011		6
38	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006 , 8, 193-9	3.6	13
37	The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. <i>Clinical and Translational Oncology</i> , 2006 , 8, 508-18	3.6	12
36	Elevated Serum Levels of Vascular Endothelial Growth Factor Are Associated With Tumor-Associated Macrophages in Primary Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2006 , 125, 111-118	1.9	26
35	An uncommon presentation of non-Hodgkin's lymphoma: diffuse large-cell lymphoma presenting as a peritoneal mass. <i>Leukemia and Lymphoma</i> , 2006 , 47, 933-4	1.9	
34	A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. <i>Radiotherapy and Oncology</i> , 2006 , 79, 34-8	5.3	46
33	Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 389-92		5
32	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
31	Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. <i>Breast Cancer Research and Treatment</i> , 2005 , 94, 265-72	4.4	49
30	Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2067-2067	2.2	1
29	Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Alamo project (1990-1997). <i>Journal of Clinical Oncology</i> , 2005 , 23, 585-585	2.2	2
28	Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). <i>Journal of Clinical Oncology</i> , 2004 , 22, 961-2	2.2	14
27	Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. <i>Annals of Oncology</i> , 2004 , 15, 1798-804	10.3	55
26	Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004 , 15, 79-87	10.3	55

25	A Neural Network Based Model for Prognosis of Early Breast Cancer. <i>Applied Intelligence</i> , 2004 , 20, 231-238	10
24	Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2587-93	2.2 109
23	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 507-507	2.2 2
22	Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 596-596	2.2 5
21	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation. <i>International Journal of Biological Markers</i> , 2004 , 19, 221-228	2.8 7
20	Multicenter study evaluating a dual policy of postorchietomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. <i>Annals of Oncology</i> , 2003 , 14, 867-72	10.3 91
19	Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study. <i>Breast Cancer Research and Treatment</i> , 2003 , 77, 1-8	4.4 8
18	A combined neural network and decision trees model for prognosis of breast cancer relapse. <i>Artificial Intelligence in Medicine</i> , 2003 , 27, 45-63	7.4 140
17	Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). <i>European Urology</i> , 2002 , 42, 553-62; discussion 562-3	10.2 81
16	Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. <i>British Journal of Cancer</i> , 2002 , 86, 1367-72	8.7 162
15	Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2001 , 66, 33-9	4.4 18
14	Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. <i>Leukemia and Lymphoma</i> , 2001 , 41, 353-8	1.9 14
13	Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2545-52	2.2 58
12	Variabilidad en la utilización del tratamiento conservador del cancer de mama localizado en un área geográfica 2000 , 2, 202-206	
11	BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). <i>Annals of Oncology</i> , 1999 , 10, 289-93	10.3 29
10	Irinotecan-induced central nervous system toxicity: a case report. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 647	9.7 13
9	Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1118-22	2.2 26
8	A monolayer coagglutination microplate technique for typing red blood cells. <i>Vox Sanguinis</i> , 1997 , 72, 26-30	3.1 10

7	Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 140-3	2.7	3
6	Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. <i>Annals of Oncology</i> , 1992 , 3, 31-5	10.3	5
5	Weekly First-Line Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide and Epirubicin. <i>Tumori</i> , 1992 , 78, 338-340	1.7	1
4	Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. <i>Oncology</i> , 1989 , 46, 26-30	3.6	23
3	Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 633-5		6
2	Follow-up of breast cancer stages I and II. An analysis of some common methods. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 419-23		16
1	Development of a functional assessment task in metastatic breast cancer patients: the 30-second lie-to-sit test. <i>Disability and Rehabilitation</i> , 1-8	2.4	0